CPHI
Price
$1.48
Change
+$0.06 (+4.23%)
Updated
Aug 29, 01:27 PM (EDT)
Capitalization
4.63M
TAK
Price
$14.97
Change
+$0.01 (+0.07%)
Updated
Aug 29, 04:20 PM (EDT)
Capitalization
47.45B
62 days until earnings call
Interact to see
Advertisement

CPHI vs TAK

Header iconCPHI vs TAK Comparison
Open Charts CPHI vs TAKBanner chart's image
China Pharma Holdings
Price$1.48
Change+$0.06 (+4.23%)
Volume$1K
Capitalization4.63M
Takeda Pharmaceutical
Price$14.97
Change+$0.01 (+0.07%)
Volume$586
Capitalization47.45B
CPHI vs TAK Comparison Chart in %
Loading...
CPHI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPHI vs. TAK commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPHI is a Hold and TAK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (CPHI: $1.42 vs. TAK: $14.97)
Brand notoriety: CPHI and TAK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CPHI: 65% vs. TAK: 68%
Market capitalization -- CPHI: $4.63M vs. TAK: $47.45B
CPHI [@Pharmaceuticals: Generic] is valued at $4.63M. TAK’s [@Pharmaceuticals: Generic] market capitalization is $47.45B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPHI’s FA Score shows that 0 FA rating(s) are green whileTAK’s FA Score has 1 green FA rating(s).

  • CPHI’s FA Score: 0 green, 5 red.
  • TAK’s FA Score: 1 green, 4 red.
According to our system of comparison, TAK is a better buy in the long-term than CPHI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPHI’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 7 bullish TA indicator(s).

  • CPHI’s TA Score: 5 bullish, 4 bearish.
  • TAK’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, TAK is a better buy in the short-term than CPHI.

Price Growth

CPHI (@Pharmaceuticals: Generic) experienced а -4.05% price change this week, while TAK (@Pharmaceuticals: Generic) price change was -2.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.15%. For the same industry, the average monthly price growth was +68.06%, and the average quarterly price growth was +81.85%.

Reported Earning Dates

TAK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TAK($47.4B) has a higher market cap than CPHI($4.63M). TAK YTD gains are higher at: 13.066 vs. CPHI (-38.925). TAK has higher annual earnings (EBITDA): 1.13T vs. CPHI (-1.74M). TAK has more cash in the bank: 419B vs. CPHI (625K). CPHI has less debt than TAK: CPHI (3.43M) vs TAK (4.51T). TAK has higher revenues than CPHI: TAK (4.48T) vs CPHI (4.4M).
CPHITAKCPHI / TAK
Capitalization4.63M47.4B0%
EBITDA-1.74M1.13T-0%
Gain YTD-38.92513.066-298%
P/E RatioN/A51.63-
Revenue4.4M4.48T0%
Total Cash625K419B0%
Total Debt3.43M4.51T0%
FUNDAMENTALS RATINGS
CPHI vs TAK: Fundamental Ratings
CPHI
TAK
OUTLOOK RATING
1..100
5024
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
6
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9155
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for CPHI (46) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than CPHI’s over the last 12 months.

TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CPHI (100) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to CPHI’s over the last 12 months.

TAK's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CPHI (100) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to CPHI’s over the last 12 months.

TAK's Price Growth Rating (55) in the Pharmaceuticals Major industry is somewhat better than the same rating for CPHI (91) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than CPHI’s over the last 12 months.

TAK's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CPHI (100) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to CPHI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPHITAK
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
46%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
40%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
39%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
36%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 10 days ago
41%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
53%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
39%
View a ticker or compare two or three
Interact to see
Advertisement
CPHI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GOOX34.261.27
+3.85%
T-Rex 2X Long Alphabet Daily Target ETF
SMOG119.800.73
+0.62%
VanEck Low Carbon Energy ETF
IGD5.950.03
+0.51%
Voya Global Equity Dividend AND Premium Opportunity Fund
LST38.220.08
+0.21%
Leuthold Select Industries ETF
BSCR19.68-0.02
-0.10%
Invesco BulletShares 2027 Corp Bd ETF

CPHI and

Correlation & Price change

A.I.dvisor tells us that CPHI and TAK have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPHI and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPHI
1D Price
Change %
CPHI100%
+1.43%
TAK - CPHI
26%
Poorly correlated
+0.74%
ASRT - CPHI
25%
Poorly correlated
+5.32%
HCM - CPHI
24%
Poorly correlated
-0.87%
CRON - CPHI
23%
Poorly correlated
+1.56%
PAHC - CPHI
22%
Poorly correlated
+19.44%
More

TAK and

Correlation & Price change

A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
+0.74%
HLN - TAK
42%
Loosely correlated
-0.21%
SGIOY - TAK
41%
Loosely correlated
+1.16%
ESAIY - TAK
35%
Loosely correlated
-0.26%
BNXTF - TAK
32%
Poorly correlated
N/A
ZTS - TAK
29%
Poorly correlated
-0.37%
More